BRAF and neoplasm: Molecular profiling of primary and metastatic CRCs has demonstrated high genomic [12–16] and epigenetic [17] concordance between matched primary and metastatic lesions, enabling genomic analysis of primary tumour tissue to be used to determine eligibility of metastatic CRC patients for treatment with targeted therapies such as EGFR and BRAF inhibitors.